 |
|
Rimonabant (Acomplia).
(Source: Sanofi-Aventis) |
The first direct evidence of the effects of Sanofi-Aventis’ Acomplia (rimonabant) in significantly reducing human visceral fat was recently presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes. The visceral fat area was significantly more reduced with rimonabant 20mg than with placebo. 526 obese Japanese patients with associated cardio-metabolic risk factors from 73 centers were exposed for this double-blind, placebo-controlled, parallel-group, six-month study duration, to determine the effective dose of rimonabant (5, 10, and 20mg) on body weight and multiple cardiometabolic risk factors. Inclusion criteria included at least two of the following cardiometobolic risk factors: impaired glucose tolerance, type 2 diabetes, dyslipidemia (hypertriglyceridemia and/or low HDL cholesterolemia) or hypertension.
Published in Drug Discovery & Development magazine: Vol. 10, No. 10, October, 2007, p. 32.
Filed Under: Drug Discovery
